Sjogren's disease

Looking for the plain-language version? See the patient version of this page.

Understanding this condition

What Sjogren's disease is

Systemic autoimmune exocrinopathy with lymphocytic infiltration of salivary and lacrimal glands. Presents as primary disease or in association with another connective tissue disease. Glandular features (sicca) coexist with variable extraglandular involvement. The prevailing pathogenic model is autoimmune epithelitis, in which salivary gland epithelial cells act as active drivers rather than passive targets, with early type I interferon activation, BAFF-driven B-cell activation, and germinal-centre-like structures in the glands; environmental triggers act on a genetic background including HLA, IRF5, STAT4, and IL12A.^{[1, 4, 5]}

Common symptoms

Core: keratoconjunctivitis sicca and xerostomia. Systemic burden is frequently dominated by fatigue and arthralgia. Other features include parotid or submandibular swelling, cutaneous dryness and vasculitic rashes, Raynaud phenomenon, peripheral neuropathy, interstitial lung disease, and renal tubular involvement. Sicca symptoms are present in the vast majority of patients, and systemic features occur in roughly 50 to 60 percent, with severe manifestations in about 15 to 20 percent.^{[1, 5]}

Who gets it

Marked female predominance, commonly cited around 9 to 1, with peak recognition in the fourth to sixth decades, although onset spans a wide age range. Population prevalence estimates vary by classification criteria used. Pooled prevalence is about 61 per 100,000 (43 per 100,000 in population-based studies) and pooled incidence about 6.9 per 100,000 person-years; the female-to-male ratio is roughly 9 to 11, and the mean age of patients is about 56 years, with most diagnoses between 30 and 50 years of age.^{[1, 3, 5]}

How it is diagnosed

Diagnosis integrates sicca symptoms with objective ocular tests (ocular staining score, Schirmer's), salivary assessment (unstimulated whole salivary flow), serology (anti-SSA/Ro, ANA, rheumatoid factor), and, where needed, labial salivary gland biopsy with focus score. The 2016 ACR/EULAR criteria classify for research; see the classification callout. The classification thresholds (focus score, anti-SSA, ocular staining, Schirmer, and salivary flow) are transcribed from the 2016 ACR/EULAR criteria in the classification section.^{[2, 1]}

What to expect over time

Generally chronic with a variable course; symptom burden (sicca, fatigue, pain) often outweighs organ-threatening disease, but a subset develops significant systemic involvement. The recognised increased lymphoma risk is concentrated in patients with persistent glandular swelling, cryoglobulinaemia, low complement, and high systemic activity. About 5 percent of patients develop lymphoma; excess mortality is driven mainly by B-cell lymphoma, severe organ involvement (interstitial lung disease, renal failure, and severe cryoglobulinaemic vasculitis), infection, and cardiovascular disease.^{[1, 5, 4]}

Living with and treating it

The goals of treatment

Goals: relieve sicca and constitutional symptoms, preserve glandular and organ function, treat extraglandular and systemic disease proportionately, and monitor lymphoma-risk features. Unlike RA, there is no validated treat-to-target composite; see the treat-to-target box. These goals align with the 2019 EULAR recommendations.^[1]

Treatment options

Layered, symptom- and organ-directed. Ocular: lubricants, secretagogues, and topical measures. Oral: non-pharmacologic stimulation, saliva substitutes, and muscarinic agonists (pilocarpine, cevimeline) where residual function exists. Musculoskeletal and constitutional: NSAIDs, hydroxychloroquine, short glucocorticoid courses. Organ-threatening disease: conventional immunosuppression (methotrexate, azathioprine, mycophenolate) and rituximab or cyclophosphamide for severe manifestations, selected by organ. Agent-level positioning, evidence strength, and sequencing follow the graded 2019 EULAR recommendations and the treatment ladder above.^[1]

Monitoring and check-ups

Periodic review of glandular and systemic activity, dental and ophthalmologic surveillance, and vigilance for lymphoma-risk features (persistent glandular enlargement, new lymphadenopathy, cryoglobulins, falling complement). Drug-specific laboratory monitoring is on each medication guide. Review intervals are individualised to disease activity rather than fixed.^[1]

Flares and when they happen

Sicca is typically persistent; extraglandular manifestations (articular, cutaneous, pulmonary, neurologic) may relapse and remit and prompt short-term escalation. Sicca is typically persistent while extraglandular manifestations relapse and remit; there is no validated flare definition, and escalation is driven by organ-specific severity on the ESSDAI rather than a fixed threshold.^{[1, 5]}

Living well with Sjogren's

Self-management centres on structured sicca care (ocular lubrication, oral hydration and stimulation, meticulous dental prophylaxis, environmental humidification), review of anticholinergic and drying agents, smoking cessation, fatigue and activity pacing, and attention to mood and genital dryness. Non-pharmacological support, including structured dryness care and exercise for musculoskeletal pain, follows the 2019 EULAR recommendations.^[1]

Related conditions to watch for

Associations include other connective tissue diseases and autoimmune thyroiditis. Complications of sicca include dental caries and corneal damage. Systemic associations include peripheral neuropathy, interstitial lung disease, and renal tubular acidosis. The increased lymphoma risk and, in anti-Ro/SSA positive patients, neonatal lupus and congenital heart block in pregnancy are important to flag. Pregnancy detail is in the RheumPreg atom, not duplicated. Reported frequencies include arthralgia in 60 to 70 percent, cutaneous vasculitis in about 10 percent, Raynaud phenomenon in about 13 percent, and renal tubular acidosis in about 9 percent; anti-Ro/SSA is found in up to 70 percent and antinuclear antibodies in over 80 percent.^{[1, 5]}

What to expect at your appointment

Initial assessment: sicca and systemic history, examination of glands, joints, skin, and a screen for extraglandular involvement, with serology and objective ocular and salivary testing, and referral for biopsy where indicated. Shared plan prioritised by symptom burden. Care may be delivered through rheumatologist-led, nurse-led, NP or PA, or ACPAC-trained extended-role practitioner models, presented non-exclusively. The initial visit covers a sicca and systemic history, examination of the salivary and lacrimal glands, joints, skin, and lymph nodes, autoantibody testing (anti-Ro/SSA, anti-La/SSB, antinuclear antibodies, and rheumatoid factor), and consideration of labial salivary gland biopsy and ocular and salivary function tests.^{[1, 5]}

2016 ACR/EULAR classification items · classify if score 4 or more of a possible 9

The criteria apply only after excluding a prior diagnosis of head and neck radiation, active hepatitis C (positive PCR), acquired immunodeficiency syndrome, sarcoidosis, amyloidosis, graft-versus-host disease, or IgG4-related disease. Anyone taking anticholinergic medicines should be assessed for objective dryness after a suitable interval off them. The criteria are for research and trial entry and are not intended to diagnose an individual.

Treatment ladder

1. 1

   Foundation for everyone: dryness care and protection

   Universal base: ocular lubricants and topical ocular measures, oral non-pharmacologic stimulation and saliva substitutes, meticulous dental prophylaxis, environmental humidification, and review of drying or anticholinergic agents. No dedicated drug guide exists for tears or saliva substitutes.

   Reconciled with the 2019 EULAR recommendations (Ramos-Casals 2020): topical dryness care is the first approach for everyone (overarching principle B).

2. 2

   Boost secretions and treat joint and fatigue symptoms

   Muscarinic agonists (pilocarpine, cevimeline) where residual glandular function remains; hydroxychloroquine and NSAIDs for musculoskeletal and constitutional symptoms; short glucocorticoid courses for flares. Hydroxychloroquine's evidence base in Sjogren's is limited. Secretagogues have no dedicated drug guide yet.

   Reconciled with EULAR 2020: muscarinic agonists for residual glandular function (recommendation 2, GoR B) and analgesics or NSAIDs for musculoskeletal pain (recommendation 6, GoR C). Hydroxychloroquine's pivotal randomised trial did not meet its primary endpoint, so its role is limited to selected articular symptoms.

3. 3

   Organ or systemic involvement

   Add conventional immunosuppression guided by the organ and severity (methotrexate, azathioprine, mycophenolate). Selection is organ-directed rather than protocol-driven.

   Reconciled with EULAR 2020: immunosuppressive agents are used mainly as glucocorticoid-sparing agents, with no evidence favouring one agent, tailored to organ-specific severity by ESSDAI (recommendations 7 and 9).

4. 4

   Severe or refractory disease

   Rituximab or cyclophosphamide for severe or refractory systemic manifestations (for example cryoglobulinaemic vasculitis or severe neuropathy), organ-directed. Evidence in Sjogren's is mixed and indication-specific.

   Reconciled with EULAR 2020: B-cell targeted therapy (rituximab) for severe, refractory systemic disease, best supported for cryoglobulinaemia-associated vasculitis (recommendation 10, GoR B), within a sequential use of glucocorticoids, immunosuppressives, and biologics (recommendation 11).

Guideline recommendations

Key points

Medication guides

Plain-language guides to the medicines used for this condition. Each has a patient and a clinician view.

• Hydroxychloroquine
• NSAIDs
• Glucocorticoids
• Methotrexate
• Azathioprine
• Mycophenolate
• Rituximab
• Cyclophosphamide

Key numbers

• Marked female predominance, commonly cited near 9 to 1. Meta-analysis gives a female-to-male ratio of 9.15 in incidence data and 10.72 in prevalence data.^{[1, 3]}

References

1. Ramos-Casals M, Brito-Zeron P, Bombardieri S, et al; EULAR-Sjogren Syndrome Task Force Group. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi:10.1136/annrheumdis-2019-216114 https://doi.org/10.1136/annrheumdis-2019-216114
2. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35-45. doi:10.1002/art.39859 https://doi.org/10.1002/art.39859
3. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015;74(11):1983 to 1989. doi:10.1136/annrheumdis-2014-205375 https://doi.org/10.1136/annrheumdis-2014-205375
4. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol 2013;9(9):544 to 556. doi:10.1038/nrrheum.2013.110 https://doi.org/10.1038/nrrheum.2013.110
5. Brito-Zeron P, Baldini C, Bootsma H, et al. Sjogren syndrome. Nat Rev Dis Primers 2016;2:16047. doi:10.1038/nrdp.2016.47 https://doi.org/10.1038/nrdp.2016.47